ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...
Uncertainty defined the conversation as FTR addressed the challenges facing the Class 8 market industry. “This is not the cycle you were planning for,” FTR CEO Jonathan Starks told attendees Monday at ...
Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results